Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
Hoth Therapeutics is a development stage biopharmaceutical company focused on prop...
Hoth Therapeutics is a development stage biopha...
Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin ...
Sophiris Bio Inc. is a late-stage biopharmaceut...
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients w...
At ACADIA (NASDAQ: ACAD), we share a passion fo...
Eton Pharmaceuticals, Inc. is a Deer Park, IL-based biopharmaceutical company focu...
Eton Pharmaceuticals, Inc. is a Deer Park, IL-b...
IDEAYA is an oncology-focused precision medicine company committed to the discover...
IDEAYA is an oncology-focused precision medicin...
Heat Biologics a biopharmaceutical company that develops immunotherapies with the ...
Heat Biologics a biopharmaceutical company that...
We are ProQR, a company on a mission to create new medicines for patients in need....
We are ProQR, a company on a mission to create ...
Join the National Investor Network and get the latest information with your interests in mind.